ARCT
USDArcturus Therapeutics Holdings Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$9.170
고가
$9.400
저가
$8.840
거래량
1.18M
기업 기본 정보
시가총액
242.5M
산업
생명공학
국가
United States
거래 통계
평균 거래량
1.22M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.
Guggenheim Downgrades Arcturus Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기